BIOTECHNOLOGY
tumour’s local immune suppression microenvironment and break the host immune tolerance state, showing great application potential and development prospects in the clinical treatment of tumours. However, there are also risks of cytokine storm, off-target effect, insertion mutation and other clinical applications.
CAR T-CELL THERAPY IN HAEMATOLOGIC CANCER CAR T-cell therapy has gained an initial foothold in bloodborne cancers. CAR T-cell-based therapies with high efficacy are widely used in haematological cancers such as acute and chronic forms of leukaemia, lymphoma and myeloma. Anti-CD19 CAR T-cells are effective
for treatingR/R (relapsed or refractory) B-cell malignancies, such as B-cell non- Hodgkin lymphoma (NHL), ALL and chronic lymphocytic leukaemia in both paediatric and adult patients. CD19, a member of the immunoglobulin superfamily expressed on the surface of B cells, serves as an ideal target for car-targeted therapy. Phase 2 of the multicentre ELIANA trial saw a complete remission rate of 60% in 75 children and young adults, an overall remission rate of 81%, a durable remission rate of 80%, and a six-month relapse-free survival associated with prolonged CAR T-cells in peripheral blood samples and sustained B-cell proliferation. Te CD22-CAR T-cell can target
another overexpressed antigen on B-cell tumours, CD22. Te impressive
Fig.1. Examples of high- quality HER2 proteins
antitumour function of CD22-CAR T cell was reported in relapsed cancer after CD19-CAR T-cell therapy or in an era directing all tumour cells. Moreover, several studies have confirmed the safety and efficacy of CD20-CAR T-cells in R/R NHL, follicular and set-in-cell lymphoma. Sino Biological provides several
recombinant haematologic tumour target proteins, ELISA kits and more. Various methods have validated these high-quality reagents and will provide consistent and reproducible results.
CAR T-CELL THERAPY IN SOLID TUMOURS Targeting solid tumours is more complex than targeting hematologic cancers, and CAR T-cells have a set of challenges
to address. Te genetic instability of tumour cells means that they can stop expressing the antigens targeted by T-cells or lack the mechanism to present these antigens. Solid tumours in clinical trials are
growing, including CAR T-cells targeting carcinoembryonic antigen, mesothelin, interleukin 13 receptor alpha(IL- 13Ralpha), human epidermal growth factor receptor 2(HER2), fibroblast activation protein(FAP), L1 cell adhesion molecule(L1CAM) and epidermal growth factor receptor. HER2, a tyrosine kinase receptor,
is overexpressed in many cancers and approximately 80% of glioblastoma. HER2 plays a crucial role in development, cell proliferation and differentiation. HER2 gene has been associated with malignancy and a poor prognosis in many carcinomas, including breast, prostate, ovarian, lung cancers, etc. It has been shown that third-generation HER2 CAR T-cells can target and kill glioblastoma cells. Efficacy was significantly improved when combined with PD-1 blockade. Sino Biological provides broad CAR T-cell therapy targets with high activity and purity (Fig. 1). CAR T-cells were one of the popular
critical advances in cancer immunotherapy at the beginning of this century. Tey will be an essential immunological technology in the 21st century, ultimately defeating fatal diseases such as cancer.
CAR T-cell therapy will play a key role in defeating cancer
44
www.scientistlive.com
Dr Emma Zhao is with Sino Biological.
www.sinobiological.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
